orantinib has been researched along with pemetrexed in 1 studies
| Studies (orantinib) | Trials (orantinib) | Recent Studies (post-2010) (orantinib) | Studies (pemetrexed) | Trials (pemetrexed) | Recent Studies (post-2010) (pemetrexed) |
|---|---|---|---|---|---|
| 110 | 19 | 36 | 2,469 | 657 | 1,695 |
| Protein | Taxonomy | orantinib (IC50) | pemetrexed (IC50) |
|---|---|---|---|
| Thymidylate synthase | Escherichia coli | 1.1 | |
| Dihydrofolate reductase | Homo sapiens (human) | 4.0309 | |
| Dihydrofolate reductase | Lacticaseibacillus casei | 2.3 | |
| Thymidylate synthase | Homo sapiens (human) | 8.1787 | |
| Dihydrofolate reductase | Escherichia coli K-12 | 2.3 | |
| Folate receptor beta | Homo sapiens (human) | 0.2585 | |
| Folate receptor alpha | Homo sapiens (human) | 0.2417 | |
| Trifunctional purine biosynthetic protein adenosine-3 | Homo sapiens (human) | 0.0342 | |
| Bifunctional purine biosynthesis protein ATIC | Homo sapiens (human) | 0.07 | |
| Reduced folate transporter | Homo sapiens (human) | 0.0928 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Toxoplasma gondii | 1.655 | |
| Proton-coupled folate transporter | Homo sapiens (human) | 0.0229 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bailey-Downs, LC; Gangjee, A; Ihnat, MA; Kisliuk, RL; Thorpe, JE; Zhao, Y | 1 |
1 other study(ies) available for orantinib and pemetrexed
| Article | Year |
|---|---|
Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Drug Screening Assays, Antitumor; Humans; Indenes; Melanoma, Experimental; Mice; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta | 2012 |